The value of molecular monitoring for residual disease (MRD) in early morphological remitters among adults diagnosed with B cell ALL and treated according to the MRC UKALL12 protocol.

Documenti analoghi

• Molecular monitoring of residual disease (MRD) during induction and intensification phases in low risk adult B cell ALL treated according to the MRC UKALL12 protocol.
  di: Foroni, L, et al.
  Pubblicazione: (2005)
• Value of molecular monitoring for minimal residual disease preceding autologous SCT following diagnosis of B cell acute lymphoblastic leukemia in patients treated with the MRC UKALL12 protocol.
  di: Foroni, L, et al.
  Pubblicazione: (2005)
• Clinical effect of Imatinib following remission induction in adult Philadelphia chromosome-positive acute lymphoblastic leukaemia: early results from the MRC UKALL12 Study
  di: Patel, B, et al.
  Pubblicazione: (2006)
• Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
  di: Fielding, A, et al.
  Pubblicazione: (2007)
• The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study
  di: Patel, B, et al.
  Pubblicazione: (2005)